First Experience with Rapamycin-Based Immunosuppression to Improve Kidney Function After Heart Transplantation

Abstract

This study was designed to gain initial experience with rapamycin in thoracic organ transplant recipients with severely compromised kidney function, i.e. to see whether and how kidney function will improve with a rapamycin-based immunosuppressive protocol. Methods: Twelve heart transplant patients were included into the study (serum creatinine > 2.5 mg/dL), with an average time after transplantation of more than 4 years. The calcineurin inhibitor (cyclosporine A = 9, tacrolimus = 3) was reduced by 50 %, and rapamycin added to reach a target level of 8 - 12 ng/dL. Azathioprine was halted, corticosteroid treatment remained unchanged. Results: After implementing the rapamycin-based immunosuppression kidney function improved in all patients within one week. Serum creatinine dropped from 3.1 ± 0.6 mg/dL to 2.7 ± 0.5 mg/dL (p = 0.0004), creatinine clearance increased from 30.4 ± 11 mL/min to 40.8 ± 10.5 mL/min (p = 0.003). This improvement continued until 3 months after the conversion (p = 0.032). Thereafter, no statistically significant changes were noted up to 6 months posttransplant (p = 0.41). Serum cyclosporine levels dropped from 180 ± 40 ng/mL to 132 ± 46 ng/mL on average (p = 0.002). Side-effects occurred in 4 patients and were all related to a rapamycin level exceeding 12 ng/mL. Conclusions: We conclude that transplant patients with impaired kidney function will have an immediate benefit from partially replacing calcineurin inhibitors by rapamycin.

Heart transplantation - immunosuppression - rapamycin - kidney failure

References

• 1 Hertz M, Taylor D, Trulock E. et al . The registry of the International Society for Heart and Lung Transplantation: nineteenth official report - 2002.  J Heart Lung Transplant. 2002;  21 950-970
• 2 Sehgal S N, Baker H, Vezina C. Rapamycin (AY-22 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.  J Antiobiot (Tokyo). 1975;  28 727-732
• 3 Schmid C, Heemann U, Azuma H, Tilney N L. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.  Transplantation. 1995;  60 729-733
• 4 Taylor P J, Johnson A G. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospary tandem mass spectrometry.  J Chromatography B. 1998;  721 285-294
• 5 Bennett W M, DeMattos A, Meyer M M, Andoh T, Barry J M. Chronic nephropathy: the Achilles' heel of immunosuppressive therapy.  Kidney Int. 1996;  50 1089-1100
• 6 Healy E, Dempsey M, Lally C, Ryan M P. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line.  Kidney Int. 1998;  54 1955-1966
• 7 Groth C G, Backman L, Morales J M. et al . Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.  Transplantation. 1999;  67 937-938
• 8 Johnson R WG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.  Transplantation. 2001;  72 777-786
• 9 Johnson R W. Sirolimus (Rapamune) in renal transplantation.  Curr Opin Nephrol Hypertens. 2002;  11 603-607
• 10 Snell G I, Levvey B J, Chin W. et al . Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment.  J Heart Lung Transplant. 2002;  21 540-546
• 11 Hariharan S. et al . Pharmacokinetics (PK) and tolerability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients.  Am J Transplant. 2001;  1 (Suppl 1) 406